A systematic review of a single-class maintenance strategy with nucleoside/nucleotide reverse transcriptase inhibitors in HIV/AIDS.

Abstract:

BACKGROUND:Single-drug class regimens with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are generally not recommended as initial therapy because they are inferior compared with therapy with two NRTIs plus efavirenz. However, triple-NRTI combinations can be useful in specific circumstances such as in tuberculosis coinfection, pregnancy or dyslipidaemia. Here, we review the potential of such combinations to maintain viral suppression after induction of suppression by standard combination antiretroviral therapy (cART) and to evaluate the trade-off of NRTI-only regimens for metabolic control. METHODS:We conducted a systematic search of the literature in two databases from 1 January 1998 up to 1 March 2013: Medline, through the search engine PubMed, and Embase. RESULTS:A total of 11 randomized controlled trials (RCTs) with 2,105 patients and 3 observational studies with 2,639 patients were included. Studies including patients with mono- or dual-NRTI treatment before start of effective cART showed a tendency to higher failure rate because of resistance based on archived viral mutations. In studies with ART-naive subjects before start of cART, triple-NRTI combination showed virological activity comparable to two NRTIs plus a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in all RCTs, but not in one cohort study. Switching improved serum lipids significantly. CONCLUSIONS:Of the studied triple-NRTI combinations only abacavir/lamivudine/zidovudine was sufficiently potent. Triple-NRTI maintenance after successful induction with two-class cART appeared successful in treatment-naive subjects and remains a useful option in specific circumstances, especially when other drugs are not available or drug interactions are an issue.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Sprenger HG,Bierman WF,van der Werf TS,Gisolf EH,Richter C

doi

10.3851/IMP2726

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

625-36

issue

7

eissn

1359-6535

issn

2040-2058

journal_volume

19

pub_type

杂志文章,meta分析,评审
  • Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

    abstract:OBJECTIVES:To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg). DESIGN:Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Colombo S,Buclin T,Franc C,Guignard N,Khonkarly M,Tarr PE,Rochat B,Biollaz J,Telenti A,Decosterd LA,Cavassini M

    更新日期:2006-01-01 00:00:00

  • Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.

    abstract:BACKGROUND:The H275Y neuraminidase mutation conferring oseltamivir resistance has been reported in several pandemic A/H1N1 (pH1N1) isolates. We sought to evaluate transmission of this mutant virus through the direct contact and the airborne (aerosol and droplet) routes in the ferret model. METHODS:Groups of four ferre...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1794

    authors: Hamelin ME,Baz M,Bouhy X,Beaulieu E,Dubé K,Mallett C,Boivin G

    更新日期:2011-01-01 00:00:00

  • Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.

    abstract:BACKGROUND:Cerebrospinal fluid (CSF) HIV RNA is commonly used as a marker of compartmental antiviral activity in HIV-positive patients. Undetectable CSF HIV RNA levels have been associated with low CSF neopterin levels and better neurocognitive performances. The aim of this study was to analyse the prevalence and predi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3140

    authors: Motta I,Allice T,Romito A,Ferrara M,Ecclesia S,Imperiale D,Ghisetti V,Di Perri G,Bonora S,Calcagno A

    更新日期:2017-01-01 00:00:00

  • Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.

    abstract::Here, we describe a case of an HIV-infected patient with right lower limb oedema that appeared after initiation of tenofovir and emtricitabine treatment. The patient was fully investigated by serial heart and vessel echo-Doppler examination. Oedema of the lower limb was attributed to a transient drug-induced fivefold ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1302

    authors: Periard D,Yerly P,Hayoz D,Mazzolai L,Widmeier A,Cavassini M

    更新日期:2009-01-01 00:00:00

  • Does antiviral therapy prevent hepatocellular carcinoma?

    abstract::Chronic infection with HBV or HCV can lead to the development of hepatocellular carcinoma (HCC). The major risk factors for HBV-related HCC are persistent presence of hepatitis B e antigen (HBeAg) and/or high serum HBV DNA levels, and cirrhosis. The major risk factor for HCV-related HCC is cirrhosis. One randomized do...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1895

    authors: Kwon H,Lok AS

    更新日期:2011-01-01 00:00:00

  • In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.

    abstract::Compounds that can block the CXCR4 chemokine receptor are a promising new class of antiretroviral agents. In these experiments we studied the effect of a modified form of the native stromal cell-derived factor-1 (SDF-1), Met-SDF-1beta. The in vitro susceptibility of two different CXCR4-tropic HIV-1 strains was determi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Rusconi S,Merrill DP,La Seta Catamancio S,Citterio P,Bulgheroni E,Croce F,Chou TC,Yang OO,Herrmann SH,Galli M,Hirsch MS

    更新日期:2000-09-01 00:00:00

  • Effect of long-term lamivudine in chronic hepatitis B virus-infected children.

    abstract:OBJECTIVE:To evaluate, retrospectively, biochemical, serological and histological responses in chronic hepatitis B (CHB)-infected children who received combination therapy and continued with prolonged treatment with lamivudine (3TC). PATIENTS AND METHODS:CHB infection was defined as the presence of hepatitis B surface...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Ozgenç F,Arikan C,Sertoz RY,Nart D,Aydogdu S,Yagci RV

    更新日期:2004-10-01 00:00:00

  • Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.

    abstract::Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3362

    authors: Xie X,Jiang Y,Zeng Y,Liu H

    更新日期:2020-06-04 00:00:00

  • HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.

    abstract:BACKGROUND:Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also a...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP2938

    authors: Gomes-Gouvêa MS,Ferreira AC,Teixeira R,Andrade JR,Ferreira AS,Barros LM,Rezende RE,Nastri AC,Leite AG,Piccoli LZ,Galvan J,Conde SR,Soares MC,Kliemann DA,Bertolini DA,Kunyoshi AS,Lyra AC,Oikawa MK,de Araújo LV,Carril

    更新日期:2015-01-01 00:00:00

  • The role of stavudine in the management of adults with HIV infection.

    abstract::Combinations of two nucleoside analogue reverse transcriptase inhibitors plus a third agent represent the current standard for antiretroviral therapy. Stavudine is a nucleoside analogue that demonstrates in vitro activity against human immunodeficiency virus type 1 (HIV-1) and HIV-2 within an acceptable therapeutic in...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:

    authors: Moyle GJ,Gazzard BG

    更新日期:1997-12-01 00:00:00

  • Biphasic pattern of depression and its predictors during pegylated interferon-based therapy in chronic hepatitis B and C patients.

    abstract:BACKGROUND:It remains unclear whether depression in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) during pegylated interferon-based therapy is associated with the virus, drug or ethnic background. We aimed to perform a prospective study to evaluate the clinical course of depression and its predictors in conse...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2441

    authors: Huang YW,Hu JT,Hu FC,Chang CJ,Chang HY,Kao JH,Yang SS,Chen DS

    更新日期:2013-01-01 00:00:00

  • The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

    abstract:BACKGROUND:The nucleotide analogue, tenofovir, has been shown to lower plasma atazanavir levels in pharmacokinetic trials, an interaction that may be partly reversed by the addition of ritonavir, whereas plasma tenofovir levels are themselves raised when the drug is combined with lopinavir/ritonavir. OBJECTIVE:To inve...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kruse G,Esser S,Stocker H,Breske A,Koerber A,Kopperman M,Wiehler H,Ross B,Möcklinghoff C,Hill A,Becker M,Kurowski M

    更新日期:2005-01-01 00:00:00

  • The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.

    abstract:BACKGROUND:Peripheral neuropathy (PN) in HIV-infected individuals is thought be due to a toxic effect on mitochondria induced by some nucleoside reverse transcriptase inhibitors (NRTI). METHODS:A time-to-event analysis was performed using data from the Delta trial to study the incidence of PN in HIV-infected individua...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:

    authors: Arenas-Pinto A,Bhaskaran K,Dunn D,Weller IV

    更新日期:2008-01-01 00:00:00

  • The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.

    abstract:BACKGROUND:Drug-resistant HBV mutants frequently arise during nucleoside/nucleotide analogue (NA) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. The enrichment of immune-escape mutations was negatively correlated with hepatitis B surface antigen (HBsAg) clearance un...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3156

    authors: Shan M,Shen Z,Sun H,Zheng J,Zhang M

    更新日期:2017-01-01 00:00:00

  • Targeting human papillomavirus genome replication for antiviral drug discovery.

    abstract::Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2612

    authors: Archambault J,Melendy T

    更新日期:2013-01-01 00:00:00

  • Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.

    abstract:BACKGROUND:Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy. Seven patients showed a delayed response to tenofovir. The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1940

    authors: Lada O,Gervais A,Branger M,Peytavin G,Roquebert B,Collin G,Fraqueiro G,Moucari R,Leclerc L,Martinot-Peignoux M,Matheron S,Marcellin P

    更新日期:2012-01-01 00:00:00

  • Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study.

    abstract:BACKGROUND:Limited data suggest that glycated haemoglobin (haemoglobin A1c; A1C) values might not reflect glycaemic control accurately in HIV-infected individuals with diabetes. METHODS:We evaluated repeated measures of paired fasting glucose and A1C values in 315 HIV-infected and 109 HIV-uninfected diabetic participa...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1557

    authors: Glesby MJ,Hoover DR,Shi Q,Danoff A,Howard A,Tien P,Merenstein D,Cohen M,Golub E,Dehovitz J,Nowicki M,Anastos K

    更新日期:2010-01-01 00:00:00

  • MicroRNAs: role and therapeutic targets in viral hepatitis.

    abstract::MicroRNAs regulate gene expression by binding to the 3'-untranslated region (UTR) of target messenger RNAs (mRNAs). The importance of microRNAs has been shown for several liver diseases, for example, viral hepatitis. MicroRNA-122 is highly abundant in the liver and is involved in the regulation of lipid metabolism. Mi...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2766

    authors: van der Ree MH,de Bruijne J,Kootstra NA,Jansen PL,Reesink HW

    更新日期:2014-01-01 00:00:00

  • Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.

    abstract:BACKGROUND:Rilpivirine-based regimens are now preferred or alternative first-line regimens according to many HIV treatment guidelines. Recently, a surveillance study conducted in Argentina determined that prevalence of pretreatment resistance to first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3147

    authors: Bissio E,Barbás MG,Kademián S,Bouzas MB,Salomón H,Cudolá A,Giuliano SF,Falistocco C

    更新日期:2017-01-01 00:00:00

  • Tenofovir-based antiretroviral therapy in 
HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database.

    abstract:BACKGROUND:The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. METHODS:HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observation...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP2972

    authors: Boettiger DC,Kerr S,Ditangco R,Chaiwarith R,Li PC,Merati TP,Pham TT,Kiertiburanakul S,Kumarasamy N,Vonthanak S,Lee CK,Van Kinh N,Pujari S,Wong WW,Kamarulzaman A,Zhang F,Yunihastuti E,Choi JY,Oka S,Ng OT,Kantipong

    更新日期:2016-01-01 00:00:00

  • Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen.

    abstract:BACKGROUND:Poor adherence to antiretroviral therapy contributes to pharmacokinetic variability and is the major determinant of virological failure. However, measuring treatment adherence is difficult, especially in children. We investigated the relationship between plasma lopinavir concentrations, pretreatment characte...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2749

    authors: Moholisa RR,Schomaker M,Kuhn L,Meredith S,Wiesner L,Coovadia A,Strehlau R,Martens L,Abrams EJ,Maartens G,McIlleron H

    更新日期:2014-01-01 00:00:00

  • Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.

    abstract::Solid organ transplantation in HIV-infected individuals requires concomitant use of immunosuppressants and antiretrovirals that may cause significant drug interactions. Here we report on a peculiar pharmacokinetic interaction between tacrolimus and protease inhibitors (PIs) which occurred in four HIV-infected liver tr...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Pea F,Tavio M,Pavan F,Londero A,Bresadola V,Adani GL,Furlanut M,Viale P

    更新日期:2008-01-01 00:00:00

  • Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.

    abstract:BACKGROUND:The potential use of variola virus as a biological weapon has renewed efforts in the development of antiviral agents against orthopoxviruses. ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] is an anti-orthopoxvirus compound active ag...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Duraffour S,Snoeck R,de Vos R,van Den Oord JJ,Crance JM,Garin D,Hruby DE,Jordan R,De Clercq E,Andrei G

    更新日期:2007-01-01 00:00:00

  • Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

    abstract:BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Verheyen J,Litau E,Sing T,Däumer M,Balduin M,Oette M,Fätkenheuer G,Rockstroh JK,Schuldenzucker U,Hoffmann D,Pfister H,Kaiser R

    更新日期:2006-01-01 00:00:00

  • Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells.

    abstract::In order to study the inhibitory effect of various reverse transcriptase inhibitors (RTIs) on cell-free HIV, we adapted a recently described in vitro system, based on co-cultures of dendritic cells and resting CD4 T cells, modelling early target cells during sexual transmission. The compounds tested included the secon...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Njai HF,Lewi PJ,Janssen CG,Garcia S,Fransen K,Kestens L,Vanham G,Janssen PA

    更新日期:2005-01-01 00:00:00

  • HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

    abstract:BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

    更新日期:2007-01-01 00:00:00

  • The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.

    abstract:BACKGROUND:Antibodies to liver-kidney microsome type 1 (anti-LKM-1), which are a marker of autoimmune hepatitis, are found in a minority of patients with chronic hepatitis C virus (HCV) infection. Whether interferon/ribavirin therapy is safe and effective in these patients is unclear. AIM:To describe the prevalence, c...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Monti V,Aghemo A,Rumi MG,Donato MF,Del Ninno E,Colombo M

    更新日期:2005-01-01 00:00:00

  • Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.

    abstract:INTRODUCTION:Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week rib...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1834

    authors: Merli M,Giannelli V,Gentili F,Giusto M,Simmaco M,Lionetto L,Corradini SG,Biliotti E,Attili AF,Rossi M,Taliani G

    更新日期:2011-01-01 00:00:00

  • HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?

    abstract::The current prevalence of cognitive impairment in HIV-infected individuals is surprisingly high, even in those with undetectable plasma HIV RNA. The aetiology is unknown but one possibility is inadequate control of persistent central nervous system (CNS) HIV infection. The CNS Penetration Effectiveness (CPE) rank has ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2951

    authors: Marra CM

    更新日期:2015-01-01 00:00:00

  • ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection.

    abstract:BACKGROUND:ITX 5061 is a highly potent small molecule inhibitor of scavenger receptor-B1, an integral transmembrane protein that is found in liver cells and is actively involved in the transport of HCV into hepatocytes. Currently, ITX 5061 is being investigated in monoinfected hepatitis C patients in a proof-of-concept...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2354

    authors: Hochreiter J,Lapham J,Wong-Staal F,McKelvy J,Sulkowski M,Glesby MJ,Johnson VA,Morse GD

    更新日期:2013-01-01 00:00:00